1e
19
1
49
2
2
18
1b
1d
18
38
59
1d
2 29
1d
25
Zelma C Chiesa Fuxench, MD
78
59
Sandra J. Lazarus Associate Professor in Dermatology
7
62
Department: Dermatology
4
1
b
1d
46
Contact information
47
4
3
3
3
2
4
b
1f
47
Department of Dermatology
3e University of Pennsylvania Perelman School of Medicine
23 3400 Civic Center Boulevard
2d Perelman Center for Advanced Medicine
1e 7th Floor, South Tower
2e Office #726
Philadelphia, PA 19104
26
3e University of Pennsylvania Perelman School of Medicine
23 3400 Civic Center Boulevard
2d Perelman Center for Advanced Medicine
1e 7th Floor, South Tower
2e Office #726
Philadelphia, PA 19104
2e
Office: 215-349-5557
32 Fax: 215-615-3127
24
f
32 Fax: 215-615-3127
24
13
Education:
21 9 B.S. c
4c University of Puerto Rico (Biology) Magna cum Laude, 2004.
21 9 M.D. c
55 University of Puerto Rico School of Medicine Magna cum Laude, 2008.
21 c M.S.C.E c
4f University of Pennsylvania Perelman School of Medicine, 2015.
c
3
3
21
21 9 B.S. c
4c University of Puerto Rico (Biology) Magna cum Laude, 2004.
21 9 M.D. c
55 University of Puerto Rico School of Medicine Magna cum Laude, 2008.
21 c M.S.C.E c
4f University of Pennsylvania Perelman School of Medicine, 2015.
c
1f
Post-Graduate Training
24 65 Intern in Medicine, University District Hospital, San Juan, Puerto Rico, 2008-2009.
24 8d Research Fellow, Department of Dermatology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico, 2009-2010.
24 86 Resident, Department of Dermatology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico, 2010-2013.
24 ad Post-Doctoral Fellow w/CPUP Role, Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, 2013-2016.
c
3
25
24 65 Intern in Medicine, University District Hospital, San Juan, Puerto Rico, 2008-2009.
24 8d Research Fellow, Department of Dermatology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico, 2009-2010.
24 86 Resident, Department of Dermatology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico, 2010-2013.
24 ad Post-Doctoral Fellow w/CPUP Role, Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, 2013-2016.
c
17
Certifications
28 37 American Board of Dermatology , 2013.
c
3
8d
Permanent link28 37 American Board of Dermatology , 2013.
c
2 29
21
1e
1d
24
5e
19 Atopic Dermatitis
11 Psoriasis
13 Hidradenitis
71
e 29
27
Description of Clinical Expertise
2c General Medical Dermatology19 Atopic Dermatitis
11 Psoriasis
13 Hidradenitis
71
Description of Research Expertise
5e Atopic Dermatitis, comorbidities in Atopic Dermatitis, Psoriasis, Epidemiologye 29
23
134 Chiesa Fuxench ZC, Lai Z, Kuo Y, Nawaz H, Cotliar J.: Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial. J Dermatolog Treat 36(1): 2480744, Dec 2025.
103 Narla S, Chiesa Fuxench ZC, Abuabara K, Beck LA, Chovatiya R, Thaçi D, Silverberg J: What Does Long-Term Control in Atopic Dermatitis Look Like. Dermatitis 36(6): 583-600, Nov-Dec 2025.
144 Chiesa Fuxench ZC, Wan J, Wang S, Syed MN, Shin DB, Abuabara K, Lemeshow AR, Gelfand JM: Fracture risk among adults with atopic dermatitis: A population-based cohort study in the United Kingdom. J Eur Acad Dermatol Venereol 39(9): e816-e819, Sep 2025.
147 Rau A, Leahr G, Del Pozo D, Hoffstad O, Chiesa Fuxench ZC, Grice E, Margolis DJ: Atopic Dermatitis: Association of maternal and child history of celiac disease and the child's development of atopic dermatitis. J Am Acad Dermatol 92(6): 1385-87, Jun 2025.
17f Silva GS, Gotschall JW, Hu F, Whidden E, Cunningham P, Niculcea J, Chapman C, Sharma PV, Evans G, Hussain F, Chiesa Fuxench ZC, Knox K, Rosenbach M: An Educational Intervention to Reduce Regulated Medical Waste: The Inpatient Medicine and Outpatient Dermatology Setting. Int J Dermatol 64(5): 901-08, May 2025.
1a1 Kenney HM, Yoshida T, Berdyshev E, Calatroni A, Gill SR, Simpson EL, Lussier S, Boguniewicz M, Hata T, Chiesa Fuxench ZC, De Benedetto A, Ong PY, Ko J, Davidson W, David G, Schlievert PM, Leung DYM, Beck LA: CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity. J Allergy Clin Immunol 155(2): 479-90, Feb 2025.
22c Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG; OLYMPIA 1 Investigators: Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial. JAMA Dermatol 161(2): 147-56, Feb 2025.
1bc Simpson EL, Bissonnette R, Chiesa Fuxench ZC, Kallender H, Sturm D, Ren H, Stein Gold LF: Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies. J Dermatolog Treat 35(1): 2310633, Dec 2024.
116 Rau A, Silva GS, Margolis DJ, Chiesa Fuxench ZC: Adult and infantile seborrheic dermatitis: update on current state of evidence and potential research frontiers. Int J Dermatol 63(11): 1495-1502, Nov 2024.
2c
7
1d
1f
Selected Publications
10e Meng S, Berna R, Hoffstad O, Takeshita J, Shin D, Chiesa Fuxench ZC, Margolis DJ: Epithelial Barrier Diseases Among Adult Patients with Seborrheic Dermatitis. JAMA Dermatol 162(1): 15-23, Jan 2026.134 Chiesa Fuxench ZC, Lai Z, Kuo Y, Nawaz H, Cotliar J.: Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial. J Dermatolog Treat 36(1): 2480744, Dec 2025.
103 Narla S, Chiesa Fuxench ZC, Abuabara K, Beck LA, Chovatiya R, Thaçi D, Silverberg J: What Does Long-Term Control in Atopic Dermatitis Look Like. Dermatitis 36(6): 583-600, Nov-Dec 2025.
144 Chiesa Fuxench ZC, Wan J, Wang S, Syed MN, Shin DB, Abuabara K, Lemeshow AR, Gelfand JM: Fracture risk among adults with atopic dermatitis: A population-based cohort study in the United Kingdom. J Eur Acad Dermatol Venereol 39(9): e816-e819, Sep 2025.
147 Rau A, Leahr G, Del Pozo D, Hoffstad O, Chiesa Fuxench ZC, Grice E, Margolis DJ: Atopic Dermatitis: Association of maternal and child history of celiac disease and the child's development of atopic dermatitis. J Am Acad Dermatol 92(6): 1385-87, Jun 2025.
17f Silva GS, Gotschall JW, Hu F, Whidden E, Cunningham P, Niculcea J, Chapman C, Sharma PV, Evans G, Hussain F, Chiesa Fuxench ZC, Knox K, Rosenbach M: An Educational Intervention to Reduce Regulated Medical Waste: The Inpatient Medicine and Outpatient Dermatology Setting. Int J Dermatol 64(5): 901-08, May 2025.
1a1 Kenney HM, Yoshida T, Berdyshev E, Calatroni A, Gill SR, Simpson EL, Lussier S, Boguniewicz M, Hata T, Chiesa Fuxench ZC, De Benedetto A, Ong PY, Ko J, Davidson W, David G, Schlievert PM, Leung DYM, Beck LA: CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity. J Allergy Clin Immunol 155(2): 479-90, Feb 2025.
22c Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG; OLYMPIA 1 Investigators: Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial. JAMA Dermatol 161(2): 147-56, Feb 2025.
1bc Simpson EL, Bissonnette R, Chiesa Fuxench ZC, Kallender H, Sturm D, Ren H, Stein Gold LF: Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies. J Dermatolog Treat 35(1): 2310633, Dec 2024.
116 Rau A, Silva GS, Margolis DJ, Chiesa Fuxench ZC: Adult and infantile seborrheic dermatitis: update on current state of evidence and potential research frontiers. Int J Dermatol 63(11): 1495-1502, Nov 2024.
2c